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ABSTRACT 
The large T antigen (TAg) of the polyomavirus Simian virus 40 (SV40) is known to play 
an important role in several events during the viral life cycle, including DNA replication, 
transcription, and virion assembly.  Recent analysis revealed that primary mouse embryonic 
fibroblasts (MEFs) expressing exogenous TAg showed increased transcription of interferon 
stimulated genes (ISGs).  Interestingly, this activation was shown to be stimulated in the absence 
of interferon production. The mechanisms by which TAg upregulates the pathway(s) and the 
consequences of that upregulation remain unknown. Thus, investigation into this mechanism may 
allow the elucidation of novel host factors moderating the interferon response. I tested several 
mutants of TAg to understand what functions are necessary to induce the interferon response.  My 
investigation has revealed that the early region of SV40 can activate an antiviral phenotype in 
MEFs, as seen by the attenuation of viral growth during productive infection. Furthermore, the 
amino terminus of TAg is sufficient to stimulate this response, and alternative splice forms from 
the early region (e.g. small T Antigen) do not seem to be critical to the upregulation of ISGs.  Other 
experiments indicate that the STAT1 transcription factor is necessary for establishment of the 
antiviral state. I have also shown that two human polyomaviruses, Human Polyomavirus BK 
(BKV) and human Polyomavirus JC (JCV), follow suit with our observations of SV40 TAg. I 
hypothesize that the TAg-mediated activation of ISGs contributes to an environment inhibitory for 
viral growth and that this phenomenon is extended to multiple polyomaviruses. This research 
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offers new insight into the interactions of polyomaviruses with its host.  This new knowledge could 
be used in combating human disease, and therefore serves as a valuable contribution to public 
health. 
 
 v 
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PREFACE 
I cannot express my gratitude enough for the help of my friends in the Pipas Lab, and 
everyone who has supported me through my time there.  Since my lucky inception into the lab 
during the junior year of my undergraduate education, I have been blessed to work alongside 
intelligent, understanding, and caring individuals. I could not have produced this work without 
them.  Through my experience in the lab I have learned more than I had ever hoped.  My duty now 
is to go on with the tools and experience I’ve been granted, and continue in the pursuit of science 
for the betterment of our world.  
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1.0  INTRODUCTION 
Viruses are an important part of our world and affect our lives every day. Viruses are 
nanoscopic agents that grow within the cells of organisms. They have evolved a multitude of ways 
to exploit or alter cellular processes in order to survive and spread.  Some viruses persist 
undetected, hiding in cells for years without any deleterious consequence.  While other more 
injurious viruses can cause a great deal of damage to their host, and even, although mostly 
unintentionally, lead to their death.  Studying the lifestyle and activities of viruses can serve as an 
opportunity for the elucidation of viral and cellular biology, and can also contribute to advances 
in human health.  For example, studies involving the Simian Vacuolating virus 40 (SV40) lead to 
the discovery of the tumor protein 53 (p53), a cellular transcription factor whose activity is 
abrogated in as many as 50% of all human cancers (Damania & Pipas 2009).  This example, 
among many others that could be stated, lends itself to the notion that continued study of viruses 
and their activities may offer further insight into viral/cellular biology, and possibly human 
disease. 
1.1 POLYOMAVIRUS TUMOR ANTIGENS  
Members from the family Polyomaviridae are known to cause cancer or induce tumors in 
laboratory animals.  Polyomaviridae is comprised of non-enveloped, small, dsDNA viruses. 
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Within the family are some notable kindred of the genus polyomavirus: SV40, Human 
Polyomavirus BK (BKV), and Human polyomavirus JC (JCV). SV40 has been shown to be 
capable of immortalizing and transforming primary cells in culture, and to induce tumorigenesis 
during in vivo studies of hamsters (Eddy 1962, Girardi 1962, Black 1964, Pipas 2009).  
Additionally, a few reports have shown a link between these viruses and human cancers, but other 
studies have not found any association (Bulut 2013, Shah 2007).  This link remains controversial. 
Hence, further studies of these viruses are necessary to fully understand their transformative and 
oncogenic potential as well as the mechanisms behind those phenotypes.  
Polyomaviruses encode oncogenes that are important during viral replication, but can also induce 
the transformation of certain cell types. That is, a productive polyomavirus infection in a 
permissive host normally proceeds with viral genome replication, and production of progeny 
virions.  However, occasionally in non-permissive host cells, viral replication can fail and produce 
an abortive infection (Damania & Pipas 2009).  The consequence of the latter may result in 
cellular transformation via prolonged expression of the viral oncoproteins, the tumor antigens (T 
antigens). The T antigens are among the first proteins expressed from the viral genome during its 
replicative cycle.  Specifically, they are needed to drive the host cell into S phase so as to aid in 
amplification of the viral genome and progeny assembly (Pipas 2009, Damania & Pipas 2009). 
The polyomavirus genome itself, approximately 5000bp in length, is comprised of early and late 
regions, along with a non-coding regulatory region. SV40, BKV, and JCV, share a relatively high 
degree of genome sequence homology (approximately 70%) and all transcribe T Antigens from 
within their early regions (McKees 2005).  The early regions have the potential of transcribing 
multiple differentially spliced T Antigen products. Specifically, all three encode the large T antigen 
(LTAg), and a small t antigen (sTAg).  Additionally, the 17kT antigen (17kT) from SV40, a 
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truncated T antigen from BKV, and three T prime T antigen, T’135, T’136, T’165, from JCV, and 
are also known to be made respectively (Trowbridge and Frisque 1995, Gjoerup 2010, Abend 
2009).   
1.2 POLYOMAVIRUS T ANTIGEN FUNCTIONAL DOMAINS AND CELLULAR 
TRANSFORMATION 
SV40 LTAg has multiple structural domains that induce oncogenic transformation 
(DeCaprio 2009, Pipas 2009, Levine 2009).  SV40 LTAg mediates transformation via the 
disruption of cellular p53 and retinoblastoma protein (pRB) family members (including pRB, 
p107, and p130) through activities in both its amino and carboxyl termini.  In the amino terminus, 
the J-domain (with the Hsc 70 binding motif) and the pRB binding domain, the LXCXE motif, 
work in concert to inactivate pRBs and release cellular E2F transcription factors driving S phase 
and DNA replication (Sullivan 2002). Sequences within the carboxyl-terminal half of T antigen 
bind and stabilize p53 within its ATPase domain (i.e., Walker A box motifs) (An 2012).  This 
inhibits p53 mediated regulation of the G2 to M and G1 to S phase transitions, and the ability to 
induce apoptosis (Damania & Pipas 2009). Figure 1 illustrates the three T antigens of SV40. The 
T antigens from BKV, and JCV have common features with SV40 that result in similar 
functionality (An 2012).  The LTAg of all three viruses possess a J domain, LXCXE motif, and 
Walker A boxes necessary for the establishment of cellular transformation (An 2012).  (Table one 
summarizes the few differences between domains of SV40, BKV, and JCV LTAgs.)   Furthermore, 
each virus produces smaller alternative splice products which share some of the same features.  
For example, the three T prime transcripts produced by JCV are identical in the first 132 amino 
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acids in their LTAg. Thus, they contain sequences for the J domain and LXCXE motif (Frisque 
2001).  Similarly, SV40 17kT contains both the J domain and LXCXE motif. BKV also makes a 
truncated T antigen product that is analogous to the T’ 136 from JCV, and therefore contains a J 
domain an LXCXE motif (Gjoerup 2010).    An interesting difference between SV40 small T 
antigen and those of BKV and JCV, is that those of the latter two both exhibit a J domain and 
LXCXE motifs (Gjoerup 2010).   
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 Diagrams of Simian Virus 40 tumor antigen(s): Large T antigen (708aa), 17k T antigen (135aa), and small 
T antigen (174aa).  Domains within T antigen(s) are indicated by arrows.  The “Ori” and “Zn” domains 
indicated and the origin binding domain and the zinc finger, respectively. The respective binding partners 
are indicated alongside binding sites 
Figure 1. Diagrams of Simian Virus 40 T Antigens 
 
 
 5 
Table 1. Comparison of large T Antigen 
         Viral LTAg  J Domain  
(Hsc70 Binding) 
LXCXE 
         (Rb Binding) 
         ATPase (Walker A) 
(P53 Binding) 
SV40 HPDKGG  LFCSE  G/AXXXXGKT/S  
BKV HPDKGG  LFCHE  G/AXXXXGKT/S  
JCV HPDKGG  LFCHE  G/AXXXXGKT/S  
Comparison of Large T antigen domain amino acid sequences important for transformation. 
 
1.3 T ANTIGEN ACTIVATION OF THE INTERFERON RESPONSE 
It was recently observed that the expression of the large T Antigen of SV40 in primary 
mouse embryonic fibroblasts results in the upregulation of many interferon stimulated genes 
(Rathi 2010).  Other constituents of type I and type II interferon signaling pathways were shown 
to be activated as well.  Interestingly, this phenotype was activated in the absence of interferon 
(IFN) signal production.  Under normal circumstances of viral infection, the viral nucleic acid may 
be recognized by pathogen recognition receptors such as RIG-I, or toll-like receptors (Kawai 
2006).  Binding of pathogen molecular patterns to the intracellular receptor induces a signaling 
cascade leading to the translocation of transcription factors NFκB and IRF3 to the nucleus 
(Takeuchi 2010).  In the nucleus, those factors promote the transcription of IFN-α and IFN-β 
production.  The IFN signal is translated and secreted by the infected cell so as to stimulate 
neighboring cells.  IFN receptor expressed on the surface of nearby cells bind the IFN signal and 
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stimulate type I or II IFN mediated signaling.  After binding the IFN signal, membrane associated 
kinase proteins Janus Kinase 1/2 (Jak1, Jak2) and Tyrosine Kinase (Tyk2) autophosphorylate and 
activate Signal Transducers and Activator of Transcription (STAT1/2) (Ivashkiv 2014).  At this 
point, STAT1 can heterodimerize with STAT2, then associate with IRF-9.  This results in the 
complex Interferon-stimulated gene factor 3 (ISGF3) to form.  ISGF3 then translocates to the 
nucleus and binds to Interferon stimulated response elements (ISRE) in promoters, which then 
promotes the transcription of ISGs.  Alternatively, STAT1 can homodimerize, translocate directly 
to the nucleus, and bind the gamma activated system (GAS) also promoting transcription of ISGs 
(Ivashkiv 2014).   Interferon stimulated genes are known to have various roles, but are often 
associated with antiviral activities (Schoggins 2011).  Figure 2 illustrates the type I and II IFN 
signaling pathways. 
 Studies by Verma and others in 2006 revealed elevated levels of ISG transcripts following 
transfection of primary human fetal glial cells with infectious JCV DNA. This was observed by 
microarray and real-time RT-PCR.  Additionally, a subset of ISGs examined following JC virus 
infection were also shown to be upregulated (Verma 2006).  With the observations made by Rathi 
and Verma as a foundation, this investigation sought to understand the underlying mechanism 
behind SV40 LTAg’s upregulation of the interferon response, to uncover possible consequences 
of the upregulated response, and to determine if the phenomenon could be extended to other 
polyomaviruses as well.   
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The diagram illustrates normal activation of interferon signaling.  The signaling cascade results in the 
promotion of interferon stimulated genes. 
Figure 2. Interferon Signaling Diagram 
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2.0  STATEMENT OF THE PROJECT 
Previous studies have revealed that the cellular interferon response is upregulated upon 
expression of SV40 large T Antigen in several mammalian cell lines (Rathi 2010).  Thus, I 
hypothesized that other members of the polyomaviridae family, encoding similar T Antigen 
proteins, are able to induce the interferon response; an antiviral state may result from 
activation of the response. I have investigated these hypotheses, and have attempted to uncover 
the mechanism by which the phenotype is established.   
The examination of the ability of T antigen to upregulate the interferon response was done 
so on the presumption that it may reveal previously unknown cellular factors, cellular processes, 
or viral interactions with the host.  More specifically, the possibility that the upregulation of the 
interferon response by T antigen may be important to T antigen’s ability to induce cellular 
transformation of mouse primary cells. 
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3.0  SPECIFIC AIMS 
Specific Aims: 
1. Determine if the interferon response and ISG transcription is altered in the presence of T 
Antigens from multiple polyomavirus in primary mouse embryonic fibroblast (MEFs) cells.   
I have expressed the genomic early region of polyomaviruses SV40, BKV, and JCV in primary 
mouse embryonic fibroblasts and monitor the expression of modulators of type I and II interferon 
signaling, as well as the transcription levels of their downstream products, the interferon stimulated 
genes (ISGs).  Pooled clones of MEFs expressing the virus early regions will be assessed.  We 
have chosen MEFs based on their ability to transform with T antigen expression, and the 
opportunity to perform genetic manipulation on the mice the MEFs are harvested from. 
2. Identify if an antiviral state is generated by the induction of ISGs in T Antigen expressing 
MEFs.  VSV is a virus sensitive to the interferon response. Thus, I will perform one step viral 
growth curves with the Vesicular stomatitis virus (VSV) on MEF pools expressing viral early 
regions. I will then determine if viral titer is attenuated when compared to the productive infection 
of normal MEFs. 
3. Evaluate the role of STAT1 in ISGs upregulation induced by T antigen expression. Using 
mutant mice lacking the STAT1 transcription factor, MEF pools will be produced expressing viral 
early regions. The interferon response will be examined in these pools. 
4. Identify the activity of T Antigen necessary for the upregulation of ISGs. For complete 
understanding of the viral mechanism, elucidation of the specific activity of T antigen is 
paramount. Using mutants of the viral early region, MEF pools will be generated.  These pools 
will be assayed for their ability to upregulate the interferon response. 
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4.0  MATERIALS AND METHODS 
Isolation of primary mouse embryonic fibroblasts, conditions of cell culture, and 
establishment of pools. 
Mouse embryonic fibroblasts (MEFs) and STAT1(-/-) MEFs were harvested from FVB 
embryos after 13.5 days using the method previously described (Markovics 2005).  MEFs were 
grown in DMEM (Corning #10-013-CV) supplemented with 10% fetal bovine serum 
(HYCLONE#: SH30070.03) and additionally 1% penicillin/ streptomycin (Invitrogen 
#15140163).  MEFs were grown in a 37C, 5% CO2 incubator.  MEF pools were generated via 
lentiviral transduction (Invitrogen ViraPower #K4975-00).  Transductions were carried out with 
the aid of polybrene reagent (Sigma #H9268). Lentivirus transduction conveys the pL6.3 lenti/V5 
TOPO plasmid (Invitrogen #K5315-20) expressing a genomic version of the mutant large T 
antigens (N136 equivalents, C257, or N136-3213(E107K, E108K)) under the control of the CMV 
promoter.  Plasmids were transfected with lipofectamine 2000 reagent (Invitrogen 11668-027) into 
the producer cell line, 293FT (Life technologies #R700-07) for production of lentivirus in 
accordance with manufacturer’s instructions.  Following lentiviral infection of MEFs, cells were 
grown to confluency and selected for 7-10 days in 2ug/mL blasticidin (R210-01).  Surviving 
colonies were “pooled” and passaged until passage four, when pellets were collected for further 
analysis.  MEF pools of viral early regions were generated by a similar transduction using 
retrovirus.  Genomic viral early regions were cloned into the pBABE puro plasmid (AddGene 
Plasmid 1764) and transfected into phoenix eco-cells (ATCC #CRL-3214).  Retrovirus made from 
producer cell lines were used to infect naïve MEFs.  The Large T antigen cDNA expressing pools 
were generated via introduction of pEF1/V5-HisA plasmids expressing the cDNA of the various 
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LTAg’s.  Plasmids were introduced via FUgene 6 (Promega) transfection in accordance with 
manufactuer’s instructions.   MEF pools were generated via selection for 7-10 days.  Full length 
3213 clones were a donation by Dr. M.T. Sáenz Robles, prepared by Dr. A. Rathi.  These clones 
were MEFs expressing the full length 3213 mutation.  Clones were isolated, grown, and whole cell 
protein extract samples were prepared as described below. 
One Step Viral Growth Curves and Plaque Assay.  
Wild-type MEFs or MEF pools expressing T antigen were plated in 6cm dishes and 
infected with VSV the following day at a multiplicity of infection (MOI) of 0.1.  At the time of 
infection, cells were counted to establish the correct MOI.  Based on the different growth rates of 
cells, the number of cells infected ranged from 2.5e5cells/plate to 2.5e6 cells/ plate.  The average 
of cells infected was ~9e5cells/plate, with a median of 7.5e5cells/plate. Statistical calculations for 
MEF pools and viral titer were made using R statistical software. A complete list of the number of 
cells infected for each pool is listed in table 3. Infection lasted for 1 hour in a 37C, 5% CO2 
incubator, rocking the plates every 15min.  Inoculum was removed and 2.5mL of growth medium 
was supplied.  Plates were collected at respective time points and frozen at -80C.  Viral supernatant 
was collected via centrifugation at 3000rpm for 15min. 
Infections with EMCV were performed with wt MEFs or MEF pools expressing T antigen.  
The cells were plated and allowed to grow overnight so as to reach a density of 2e6 cells/plate.  
The following day cells were counted for accuracy.  Cells were infected with EMCV at an MOI of 
0.005.  Infection lasted for one hour at 37C in a 5% CO2 incubator, rocking the plates every 15min.  
Afterward, the viral inoculum was removed; plates were washed three times in 1xPBS; 2.5mL of 
was supplied.  Plates were collected at 0, 3, and 6 hours post infection, and frozen at -80C. Viral 
supernatant was collected via centrifugation at 3000rpm for 15min. 
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Infectious virus production was quantified by way of plaque assay.  Supernatant (inoculum) 
produced from one step growth curves was serially diluted in growth media and plated on BKH21 
cells (ATCC: #CCL-10).  BHK21 cells were infected for 1 hour in a 37C, 5%CO2, incubator with 
rocking every 15min.  Inoculum was removed and 1.5% Agarose overlay (LONZA: #50100) was 
added with 2X MEM (LifeTechonologies: #61100) supplemented with 10%FBS. Twenty-four to 
36hrs post infection viral plaques were visualized with the addition of 1% neutral red solution 
(Sigma).  The same procedure was used to quantify EMCV production with two exceptions: VERO 
cells (ATCC # CCL-81) were used for viral infection, and plates were stained at 36-48 hours post 
infection to visualize plaques. 
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This table indicates the pools, number of cells at the start of infection, and the peak viral titer at 24hrs post 
infection during the VSV one-step growth curves. 
 
 
 
Table 2. MEF Pools 
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Immunoblot Analysis 
Western blots were conducted as previously described (Markovics 2005).  Dilutions of 
antibodies tested: Total STAT1 (Cell Signal #9172), Phospho-STAT1 Ser727 (Cell Signal #9177), 
Phospho-STAT1 Tyr701 (Cell Signal #9171), and Total STAT2 (Cell Signal #4597), were 
prepared in accordance with the manufacturer’s instructions.  T-Antigen mouse monoclonal 
antibodies Ab416, Ab419, and Ab901 were used as described previously (Harlow et al., 1981).  
Additional mouse monoclonal antibodies against JCV T antigens Ab962 and AB2003 were used 
as previously described (Bollag 2000, Munoz-Marmol 2004).  GAPDH loading mouse 
monoclonal was used as the loading control (US Biologicals #G8140-11). Goat anti-mouse 
(A2554), and goat anti-rabbit (A0545) from Sigma-Aldrich were used as secondary antibodies.    
Whole Cell Extract, RNA Extraction, and Reverse Transcription PCR 
MEFs and MEF pools were grown to two days post confluency, collected, and pelleted.  
Cell pellets were washed in 1x PBS and frozen at -80C.  Total RNA extraction was conducted 
using Qiagen RNeasy kit (#74104) in accordance with manufacturer’s instructions.  Samples were 
quantified using a NanoDrop2000.  
Reverse transcription PCR for the production of cDNA from 2ug total RNA was conducted 
with SuperScript III First-Strand Synthesis System for RT-PCR (#18080-051) in accordance with 
manufacturer’s instructions. PCR analysis with gene specific primers was performed using 1uL of 
cDNA and GOTaq polymerase (Promega) for 25-30cycles.  RPL5 served as the normalizing 
loading control.  The reactions were visualized with 1% agarose gels and were stained with 
ethidium bromide (Sigma-Aldrich).  Primers are listed in table 3. 
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Whole cell extract was prepared from 2-day post confluent MEF pools.  Cells were pelleted at 
3000rpm for 5 min and frozen at -80C.  Pellets were lysed in Branton’s lysis buffer (Hepes pH7.9 
50mM, KCl 0.4M, EDTA 0.5mM, NP40 0.1%, Glycerol 10%).  Lysed pellets were centrifuged 
for 15min at 4C.  Supernatant was quantified and stored at -80C.  Quantification of extract was 
performed by Bradford protein assay (BioRad) in accordance with manufacturer’s instructions.  
Bradford samples were quantified with a BioRad iMArk microplate reader. 
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Table 3: Primers Used During Study 
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5.0  RESULTS 
5.1 MULTIPLE POLYOMAVIRUS T ANTIGENS UPREGUALTE THE 
INTERFERON RESPONSE 
In order to confirm the monoclonal T antigen antibody mixture used for the detection of 
SV40 T antigen (416 & 419) can successfully cross react with BKV and JCV large T antigens, 
western blots were conducted with purified LTAg protein (purified samples were donated by Dr. 
Ping An at the University of Pittsburgh Deptartment of Biological Sciences) from SV40, BKV, 
and JCV.  Figure 3 shows a western blot of the purified proteins.  The blot shows both JCV LTAg 
and BKV LTAg proteins detected along with SV40 LTAg.  These results display that the 
antibodies used for detection of large T antigen from SV40, BKV, and JCV are indeed functional 
in their ability to detect the different polyomavirus large T antigens. 
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To assess the level of large T antigen expression in MEFs as well as the possible alternative 
splice forms, western blots using T antigen specific antibodies were performed.  Three separate 
MEF pools from different embryos were generated by lentiviral transduction to convey the 
different polyomavirus genomic early regions into the primary MEF cells. The early regions allow 
for the potential transcription of the various alternative splice forms of the large T antigen.  
Because of the transformative ability of the early regions (An 2012), the cell pools were 
immortalized.  The pools are initially a heterogeneous mixture of cells exhibiting different 
morphologies.  The different pools grew at approximately the same rate, faster than primary wild-
type MEFs, however this was not rigorously examined.  The levels of T antigen expressed by the 
pools are shown in figure 4.  Figure 4 reveals T antigen expression with a mixture of monoclonal 
antibodies (416 & 419) against sites in the amino terminus of SV40 large T antigen.  Panel A of 
the figure depicts the protein expression profile of the genomic early region (Figure 4A). The 
Comparison of purified LTAg protein from SV40 (Control), BKV, and JCV.  The 416 monoclonal 
antibody was used for detection of T Antigen. 
Figure 3: Detection of purified T antigen 
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Large T antigen product dominates for SV40 while its small T and possibly 17kT are in much 
lower proportion (Figure 4A Lane1). BKV early region appears to show no large T antigen 
expression, but does exhibit expression of either small T, or 17kT product (Lane 2).  Lane 3 shows 
expression of JCV genomic early region, and indicates a clear presence of large T product as well 
as other T prime or small T products.   
The relative abundance of large T antigen and small T antigen mRNAs was determined by 
a differential PCR that was performed with primers capable of amplifying both large and small T 
antigen transcripts simultaneously. The primers are located within the genomic sequence flanking 
the large T antigen and small T antigen introns.  Primer design locations for SV40 are depicted in 
Figure 4C.  Primers for BKV and JCV were made in similar fashion flanking the introns of large 
and small T antigens. Table 2 provides the sequences for all primers used. Figure 4B depicts the 
SV40, BKV, or JCV transcript levels of their large T antigens compared small T antigen.  The 
large T antigen products are clearly shown in greater proportion to the small T antigen for both 
SV40 and JCV. Surprisingly, the large T antigen mRNA levels for BKV also appear to be high 
relative to its small T antigen product.    
Figure 4 indicates that expression of the polyomavirus genomic early region from SV40, 
BKV, and JCV result in the production of multiple T antigen splice forms, and that the large T 
antigen dominates transcription and expression for SV40 and JCV.  Surprisingly, for BKV the 
large T antigen product seems to dominate transcription, but there does not appear to be any large 
T antigen is expressed above detectable levels.  Instead smaller products which may or may not be 
BKV small T antigen dominate expression.   Despite the differences in T antigen protein 
expression, the SV40, BKV, and JCV T antigen expressing MEFs all upregulate total STAT1/2 
protein levels, phosphorylated STAT1 protein levels, and ISG transcription. 
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To determine if the T antigens of BKV and JCV upregulate the interferon response, whole 
cell extracts were examined and total RNAs were collected from at least three separate pools of 
MEFs.  The pools expressed the genomic early region from different polyomaviruses (SV40, BKV, 
or JCV) (Figure 4A).  Western blot analysis confirmed the previous results that SV40 T antigen 
upregulates expression of total STAT1 and its activated form at the tyrosine-701 site (Rathi 2010).  
 
A B 
C 
Left Panel (A): Whole cell extract of 2 days post confluent MEF pools expressing SV40, BKV, JCV early region, or wt 
MEF cells without T Antigen (MEF).  Right Panel: (B) Reverse transcription PCR of total RNA transcript levels of ISGs 
from the pools of MEFs with T antigen or wt MEFs (MEF).  GAPDH and RPL5 serve as loading controls, respectively.  
Bottom Panel: (C) The first 651 nucleotides of the genomic T antigen region of SV40.  The blue text indicates the first 
intronic region that is spliced to produce the large T antigen.  The underlined portion indicates the intron for small T antigen.  
Primer sequences are indicated in red. 
Figure 4: Genomic Early Region Expression 
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Additionally, STAT1 activation at the serine-727 site as well as total STAT2 expression also 
increased in the presence the SV40 T-Antigen (Figure 5A).  Furthermore, a subset of the 
downstream targets of interferon induction, the ISGs, were examined by semiquantitative reverse 
transcription PCR analysis of total cellular RNA (Figure 5B). This analysis confirmed that there 
was an increase in the transcription of the ISGs examined.  The same analysis was used to examine 
pools of MEFs expressing BKV and JCV genomic early regions. Both BKV and JCV pools 
upregulated total STAT1, activated STAT1, and ISG transcripts (Figure 5).   The results reflected 
in Figure 5 hold true for all three pools examined with some exceptions.  The BKV genomic early 
region from one of three pools, did not show an upregulation of total STAT1, however that same 
pool did still show upregulation for activated STAT1 S727 (data not shown).  Tyrosine 701 (P-
STAT1) was only examined in one pool from SV40, BKV, or JCV, as the supply of antibody was 
depleted and the manufacturer discontinued production. Therefore it cannot be determined if 
activated STAT1 Y701 is upregulated in all MEF pools generated. In conclusion, the expression 
of T antigens from BKV and JCV upregulate the interferon response in MEFs similar to SV40 T 
antigen. 
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A B 
Left lane (A): Western blot of MEF pools expressing the genomic early region of SV40, BKV, JCV, or wt MEF 
cells without T Antigen (MEF).  Right lane: (B) Reverse transcription PCR of ISG subset from the pools of 
MEFs with T antigen or wt MEFs (MEF).  GAPDH and RPL5 serve as loading controls, respectively. 
Figure 5: Early region upregulation of interferon response 
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5.2 THE N-TERMINUS OF THE LARGE T ANTIGEN IS SUFFICIENT FOR THE 
INTERFERON RESPONSE  
To map the activity or activities of large T antigen necessary for ISG upregulation, a series 
of SV40, BKV, or JCV amino-terminal truncation mutants was examined. The amino truncated 
large T antigen forms carry a J-domain along with the retinoblastoma (Rb) protein binding motif 
(LXCXE) which together have been shown to bind and release E2F transcription factors leading 
to stimulation of cellular division (Sullivan 2002). Figure 6A illustrates SV40’s N-terminal 
truncation mutants. As described above, three MEF pools each were produced expressing the 
different polyomavirus N-terminal T antigen mutants.  As observed in the genomic early region 
expressing pools, these new pools grew as a heterogeneous mixture of cells with different 
morphologies.  Again, the N-Terminal mutant pools grew faster than wt MEFs.  To examine the 
level N-Terminal LTAg truncation mutants proteins are expressed in the MEF pools, western blots 
were performed to assess the level protein production, and PCR was performed to estimate the 
level of transcript mRNA.  Additionally, because the amino truncation LTAgs are expressed from 
genomic sequences truncated at the 136th amino acid, it was necessary to test for the presence of 
the stAg splice variant. Figure 7A shows the expression level of each truncation mutant protein. 
In each case a single band was observed of the expected size of the N136 mutant equivalents.  
Figure 7B depicts the differential PCR for mRNA levels of N-Term LTAg or sTAg transcript.  
Figure 7B reveals the most robust signals correspond to the expected sizes of the N-Terminal 
truncation mutants.  Thus, the dominate transcripts produced are the N-terminal mutants for all 
three polyomaviruses tested. 
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Panel A shows the first 136aa of LTAg, along with features and binding partners (N136).  Panel B shows 
the N136 –3213 mutant which is identical to N136, but has abrogated pRB binding from mutation in the 
LXCXE (N136 3213).  Panel C depicts the carboxyl truncation mutant of LTAg with features and binding 
partners.  Numbers at the ends of diagrams indicate the amino acid position corresponding to the full 
length LTAg. 
Figure 6:  SV40 Large T antigen mutant diagrams   
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Examination of three pools from SV40, BKV, or JCV revealed a consistent upregulation 
of the interferon response signaling modulators and the downstream products, ISGs (Figure 8B).  
These results were comparable with what was observed in the genomic T antigen early regions. 
However, in each of the three pools tested, total STAT2 failed was not upregulated by BKT-N138 
(Figure 8A). This was in contrast to the genomic early region expression of BKV. Finally, Figure 
8A reveals that the amino terminal truncation mutants are capable of upregulating a total levels of 
 SV40    BK     JC 
A B 
Panel A depicts a western blot using whole cell extract of 2 days post confluent MEF pools expressing the genomic 
N-terminal truncation mutant from each virus respectively.  A cocktail of TAg antibodies (416,419,2003, 701) were 
used for detection.  Panel B depicts a reverse transcription PCR of total RNA transcript levels of ISGs from the pools 
of MEFs with genomic N-Terminal T antigen or naïve wt MEFs (MEF).   
Figure 7: N-terminal Truncation Mutant Expression 
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STAT1/2, activated STAT1, and ISG transcripts. I conclude that the amino terminal truncation 
mutants comprising the first one hundred and thirty-six amino acids in SV40 (or equivalents in the 
other polyomaviruses) of the large T antigen are sufficient to upregulate the interferon response.  
The results from figures 7 and 8 indicate that the MEF pools tested preferentially transcribe and 
express the N-terminal truncation mutant, and that the mutant T antigen expression results in the 
upregulation of the interferon response.   
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1            2           3            4            5 
MEF MEF 
A B 
Panel A: Western blot analysis of MEF pools with N-terminal truncation mutants of the viral large T antigen from SV40, 
BKV, JCV, or naïve MEFs.  Panel B: ISG transcript levels from MEF pools expressing an N-Terminal truncation mutant 
of the viral large T antigen or naïve MEFs.  Lane 1B indicates upregulated ISG transcript levels from MEF pools expressing 
the genomic early region of SV40 for comparison. 
Figure 8: N-terminal Truncation Mutant Upregulation of Interferon Response 
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5.3 THE CARBOXYL-TERMINUS OF THE LARGE T ANTIGEN IS NOT 
SUFFICIENT FOR UPREGULATION OF THE INTERFERON RESPONSE 
Next domains within the carboxyl-terminal half of large T antigen were we tested, and 
unable to upregulate the interferon response in MEFs. I examined two pools of MEFs expressing 
the carboxy-terminus of the LTAg from the 257-708th amino acids (C257) (Figure 6C).  The 
pools tested were shown to express the C257 truncation mutant (Figure 9A). Western blots and 
PCRs were performed to assess the expression levels of STAT1 and STAT2, and ISG transcription 
levels (Figure 9).  Both C257 pools tested were defective for the upregulation of both total and 
activated STAT1 (Figure 9A). Interestingly, total STAT2 varied between the two pools examined, 
i.e. STAT2 was upregulated over wt in the second MEF pool tested; not the first.  Figure 9B shows 
mRNA transcript levels of selected ISGs, and in nearly every case, the ISGs did not upregulate. 
These results suggest that the in the carboxyl-terminal domains of large T antigen, cannot 
upregulate ISGs and is likely not important to the upregulation of the interferon response.   
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 Panel A depicts western blot using whole cell extract of 2 days post confluent MEF pools expressing the 
carboxyl truncation mutant (C257) from SV40 compared to naïve MEFs and MEF pools expressing the 
genomic early region of SVT.  C257 expression was tested with mouse monoclonal 901. Panel B depicts 
ISG transcription levels of C257 mutant MEF pools compared to naïve MEFs and MEF pools expressing 
the genomic early region of SVT.   
Figure 9: C-terminal truncation mutant expression 
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5.4 SMALL T ANTIGEN IT NOT NECESSARY FOR THE UPREGULATION OF 
THE INTERFERON RESPONSE 
Since the SV40 genomic early region can express at least three transcripts (large T, small 
T, and 17k T), it was tested whether the small T antigen contributes to the induction of the 
interferon response. Although the previous evidence in this study indicates a relatively low level 
of stAg transcription/ expression within the pools tested (Figures 4 & 7), it is possible that a small 
amount of the protein can upregulate the interferon response.  Thus, constructs encoding the cDNA 
of the viral LTAg that are incapable of expressing small t antigen were tested. These constructs 
were expressed in MEFs and cell pools were tested for T antigen expression and upregulation of 
the interferon response.  
To reveal the level of T antigen expression in the MEF pools possessing constructs 
encoding the cDNA of the viral LTAg, a mixture of monoclonal antibodies against SV40 TAg 
(416 and 419) and JC TAg (962 and 2003) were used in detection of T antigen (Figure 10B). The 
figure reveals expression of LTAg cDNA in the all of three pools tested (Figure 10B).  However, 
some pools may express degraded forms of the LTAg, i.e. slightly smaller appeared bands near 
the expected signal (Figure 10B).  Additionally, numerous alternative, non-small T antigen, T 
antigen splice forms are observed in the different pools for BKV and JCV (Figure 10B). 
In three separate MEF pools, western blots showed JCV able to upregulate total STAT1 in 
all three pools tested (Figure 10B).  Both SV40 and BKV showed upregulated total STAT1 in at 
least two of the three pools tested (Figure 10A).  However, in PCR for ISG transcript levels, SV40 
and BKV only showed upregulation in two of three pools tested (Figure 11).  JCV showed all 
three pools upregulating ISGs.  I conclude that pools of T antigen expressing MEFs lacking small 
T antigen were capable of upregulating the interferon response. 
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Results from figures 10 and 11 indicate that the MEFs pools tested expressing constructs 
encoding the cDNA of the viral LTAg, are capable of large T antigen expression and other T 
antigen splice products, but do not express small T antigen.  Additionally, these pools are still 
capable of upregulating the interferon response.  Together, these results suggest that small T 
antigen is not necessary in the T antigen induced upregulation of the interferon response.    
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 Panel A shows the protein levels of total STAT1 for three pools each of the different viral LTAg tested.  
Panel B shows T antigen expression in each MEF pool tested, (A,B, or, C).  The last lane of panel B shows 
SV40 genomic early region expression for comparison. 
Figure 10: Large T antigen cDNA expression 
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 Both panels show ISG transcript levels across the different MEF pools (a, b, c) expressing the LTAg cDNA 
from the corresponding virus.  The first two lanes in both panels are either naïve MEFs (MEFs), or MEF 
pools expressing the genomic early region of SV40 (SVTer). 
Figure 11: ISG Transcription in Large T cDNA pools 
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5.5 POLYOMAVIRUS T ANTIGEN INDUCES AN ANTI-VIRAL STATE 
The interferon response is normally upregulated upon pathogen detection, and the response 
results in a defensive state for the cell against the pathogen.  In this study, the pathogen VSV served 
as a measure of the antiviral state.  VSV is a positive sense RNA virus.  RNA viruses have been 
shown to be susceptible to ISG induction (e.g. OAS2) (Silverman 2007, Lin 2009, Fensterl 2012).   
To determine if large T antigen expression induces an antiviral state I tested pools of MEFs 
expressing the SV40, BKV, or JCV early regions for the ability to support VSV growth.  VSV 
growth curves were prepared by titration of supernatant harvested from MEF pools at various time 
points.  Infections in separate MEF pools expressing the different polyomavirus T antigens showed 
the production of VSV virus to be attenuated by typically 10-100 fold, with few exceptions.  
Growth curve data is illustrated in Figures 12 and 13, for the genomic early region expressing 
pools, and N-terminal truncations mutant pools, respectively.  However, both of these figures 
exhibit the identical data (i.e., the same data) for the growth of VSV on wild-type MEFs. The data 
for VSV growth on wild-type MEFs were used in both figures for comparison to either the genomic 
early region expressing pools, or the N-terminal truncations mutant pools.  Figure 12 shows that 
wt MEFs produced 1e8pfu/mL of VSV at about 12-48hrs. However, VSV growth plateaus at 
~1e6pfu/mL around 12-48 hours in MEF pools expressing the genomic early regions of SV40 or 
BKV.    JCV MEF pools appears to exhibit slower production of VSV relative to the other pools. 
However, JCV pools still eventually produced the same titer at 48hrs as SV40 and BKV (Figure 
12).  Similar to the results shown in figure 12, MEF pools expressing the N-terminal truncation 
mutant of the large T antigen produce VSV titers of ~1e6pfu/mL at 12-48hrs (Figure 13).  
However, one pool of BKV N-terminal truncation MEFs exhibited slightly higher viral titers 
(~1e7-1e8pfu/mL) between 12-48hrs (Figure 13).  
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To address the possibility that the number of cells infected during the VSV growth curve 
assays influenced virus production, statistical analyses were performed. That is, could the reduced 
viral output observed in T antigen expressing cells instead be attributed to how many cells were 
infected, and not the influence of T antigen?  While conducting the VSV growth curves described 
above, the number of cells infected varied between some experiments.  Specifically, the number 
of cells infected across experiments, both with and without a polyomavirus T antigen, had a mean 
of ~9.5e5 cells, a median of 8.5e5cells, and a range of 2.35e6 cells. However, the MOI of 0.1 was 
adjusted according for each assay based on the number of cells counted at the time of infection. 
The viral titer at 24 hours (peak of virus production) for each experiment was correlated to the 
initial number of cells infected. Only a very weak negative correlation could be observed between 
the number of cells at the time of infection and the ultimate viral output at 24hrs (Correlation = -
0.19). If it is assumed there is no influence by T antigen expression on the output of virus, this 
statistical observation confirms that the number of cells infected did not influence the production 
of virus.  Thus, the expression of T antigen must be responsible for the attenuated level of virus 
production in T antigen MEFs compared to wt MEFs. 
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 Early region pools are either SV40 (red), BKV (grey), or JCV (gold).  The X-axis indicates time points of 
collection post infection.  Viral titer is indicated on the Y-axis. Standard error of the mean is included at 
each data point. 
Figure 12: Titration of VSV growth on wt MEFs or MEF pools expressing the genomic early region 
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 Pools are either SV40 LTAg (red), BKV LTAg (grey), or JCT LTAg(gold).  The X-axis indicates time 
points of collection post infection.  Viral titer is indicated on the Y-axis. Standard error of the mean is 
included at each data point. 
Figure 13:  Titration of VSV growth on wt MEFs or MEF pools expressing the amino terminal 
truncation of large T antigen 
 
The antiviral state produced in T antigen expressing MEFs is not limited to VSV, and was 
extended to encephalomyocarditis virus (EMCV).  In order to determine if T antigen could 
attenuate EMCV growth additional growth curves were performed.  Wild type, SV40 genomic 
early region expressing MEFs, and N136 MEFs, were infected at an MOI of 0.005 over a time 
course of six hours.  At six hours post infection peak titers for both the T antigen pools and wild 
type pools were reached.  However, at 3 hours post infection a 3000-fold reduction in viral titer 
was observed in both T antigen expressing pools when compared to wild type MEFs (Figure 14).  
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Based on the evidence from both VSV and EMCV viral growth curves, it can be concluded that 
the T antigen induced interferon response in MEFs results in an antiviral state. 
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EMCV growth was examined on wt MEFs, MEF pools expressing SVT genomic early region, or MEF 
pools expressing the N-terminal truncation mutant of T antigen (N136).  The X-axis shows the time points 
of collection post infection.  Viral Titer (pfu/mL) is indicated along the Y-axis. 
Figure 14: Titration of EMCV growth   
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5.6 STAT1 TRANSCRIPTION FACTOR IS NECESSARY FOR THE INDUCTION 
OF THE ANTIVIRAL STATE 
To determine if the upregulation of ISGs by T antigen requires STAT1, pools of STAT1 
knockout MEFs expressing T antigen were examined.  The STAT1 transcription factor is an 
important mediator in IFN signaling pathways. It was shown that IFN signals (e.g IFN-α,β) are not 
produced during T Antigen expression in MEFs, but the interferon response is still upregulated 
(Rathi 2010).  Therefore, it was hypothesized that T Antigen may be reliant on type I or II IFN 
pathway mediators for ISG induction. To determine the possible importance of STAT1, T Antigen-
expressing pools were generated from MEFs generated from STAT1(-/-) mice.  As described 
earlier, whole-cell protein extract and total RNA from these pools were examined.  Pools were 
expressing T antigen as expected (Figure 15). Results showed none of the viral T antigens able to 
induce uprgeulation of ISG (Figure 16).  Figure 15 indicates that all pools not upregulating ISGs 
are still expressing the viral T antigens. In conclusion, STAT1 transcription factor is necessary for 
the upregulation of ISGs by T antigen.           
Quantification of viral (VSV) production revealed no appreciable difference between that 
produced from STAT1(-/-) MEFs and STAT1(-/-) MEFs expressing T antigen (Figure 17).  The 
levels of VSV production on wild-type MEFs and MEFs expressing the genomic early region from 
SV40 from Figure 12 are included for comparison (Figure 17).  The data from Figure 17, in 
conjunction with examination of ISGs (Figure 16), suggests STAT1 is necessary for the 
upregulation of ISGs by T antigen expression in MEFs, and that generation of the antiviral state is 
also dependent on STAT1. I conclude that the antiviral state generated by the SV40 T antigen is 
not maintained with the loss of STAT1.  
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Panel A shows the genomic early region of SV40 in STAT1(-/-) MEF pools (lane2). Normal MEF pools of 
SV40 genomic early region are included in lane 1. Panel B expression of the N-terminal truncation mutants 
for SV40, BKV, and JCV in STAT1(-/-) MEF pools (lanes 2-4). 
Figure 15: Levels of T Antigen expression in STAT1(-/-) MEF pools 
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Pools expressing the genomic early region of SV40, Panel A (lane 2).  Panel B depicts the ISG transcript levels in N-
terminal truncation mutant expression STAT1(-/-) MEF pools (lanes 4-6).  Lane 3 of panel B depict STAT1(-/-) MEFs 
without T Antigen. 
Figure 16: ISG transcript levels for STAT1(-/-) MEF pools 
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SV40 early region STAT1(-/-) MEFs (gold), or normal MEF pools expressing the genomic early region 
SV40 (red).   Wild-type MEFs are indicated in (blue), and STAT1(-/-) MEFs are indicated in (grey). The 
X-axis indicates time points of collection post infection.  Viral titer is indicated on the Y-axis. Standard 
error of the mean is included at each data point. 
Figure 17: Titration of VSV growth on STAT1(-/-) MEF pools   
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5.7 T ANTIGEN BINDING OF RETINOBLASTOMA PROTEIN FAMILY 
MEMBERS MAY BE IMPORTANT TO UPREGULATION OF THE IFN RESPONSE 
Because the truncated amino terminal mutant of LTAg from SV40, BKV, and JCV can 
upregulate the IFN response, it was hypothesized that binding of pRB family members, may be 
responsible for the upregulation of the interferon response.  Two full length SV40 LTAg 
expressing clones, and a pool expressing SV40 N136, all unable to bind pRB were examined.  The 
N136 pRB binding mutant (3213) is illustrated in Figure 6. Binding of pRB is abrogated by 
mutations at the E107K and E108K sites. The full length LTAg pRB binding mutant carries the 
same mutations, (diagram not shown). The expression of T antigen in the pRB binding mutants is 
shown in Figure 18. The evidence in Figure 19 shows that with the inability to bind pRB via the 
LXCXE motif, T antigen fails to upregulate total levels of STAT1 or STAT2 to that of its 
unmutated form.  This data requires further substantiation, but may be indicative of T antigen/pRB 
binding interaction as necessary for the upregulation of the IFN response. In conclusion, the 
binding of pRB by T antigen may be necessary to upregulate the interferon response. 
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 Lane 1 shows N136 3213 mutant lane 2 and 3 show clones of genomic full length T antigen 3213 mutants. 
Lane 4 shows genomic early region expression of SV40 for comparison. 
Figure 18: T Antigen expression in 3213 mutants 
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 Lanes 1 and 3 represent MEF pools from genomic early region from SV40 and the LTAg amino truncation 
mutant (N136), respectively.  Lane 2 is wt MEF.  Lane 4 represents MEF pool of N136 truncation with 
pRB binding mutations.  Lanes 5-6 are MEF clones expressing full length LTAg with pRB binding 
mutations.  
Figure 19: Western blot for total STAT1 or STAT2 in 3213 mutants 
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6.0  DISCUSSION 
Induction of an antiviral state is generated as a result of type I and II interferon signaling 
pathways.  These pathways upregulate products (ISGs) that inhibit virus growth by blocking viral 
mRNA translation and/or nucleic acid replication. The pathways are initiated by binding of IFN 
signal to their cognate receptors resulting in subsequent activation/dimerization of STAT 
transcription factors (referenced above). STAT dimers translocate to the nucleus and promote the 
transcription of ISGs (referenced above). The STAT1 transcription factor has been shown to be 
critical to the induction of an antiviral state (Horvath 1996). 
This study has shown that Polyomavirus T antigens upregulate the cellular interferon 
response in primary mouse cells, and that the induction results in an antiviral state.  This study has 
shown that multiple polyomavirus T antigens are capable of upregulating the interferon response.  
It was hypothesized that because the genomic early regions of polyomaviruses SV40, BKV, and 
JCV encode similar T antigen proteins, the interferon response upregulated by SV40 T antigens 
(Rathi 2010) would also be observed in cells expressing the other polyomavirus T antigens.  The 
data shown in Figure 5 shows this, and thus extends on the previous observations made by Rathi 
and others.  Figures 13 and 14 show reduced VSV production in MEFs expressing the different 
polyomavirus early regions or large T antigen amino truncation mutants, respectively.  The 
reduced virus proliferation in T antigen expressing pools compared to wt MEFs may be attributed 
to the upregulation of the interferon response and subsequent ISG production.  This likely results 
in the establishment of a cellular environment that is inhibitory to virus growth.  This study only 
examined a few of the hundreds of genes upregulated by interferon signaling, it is unclear exactly 
which ISGs are at play in the phenotype.  However, it is reasonable to conclude that the ISG profile 
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examined could be at least in part responsible for the antiviral state as their antiviral activities have 
been documented (Sadler 2008, Horvath 1996, Hallen 2007, Balan 2006, Lin 2009, Moal 2012). 
The MEF pools expressing the genomic early region from SV40, BKV, and JCV produce 
a variety of T antigen splice products.  The data from Figure 4A shows expression of both LTAg 
and smaller T antigen products that could be stAg or 17kT.  Further analysis depicted in Figure 
4B shows transcription of the LTAg clearly and a relatively small presence of stAg.  Additional 
examination has shown small T antigen transcript made in all genomic early region pools (data not 
shown).  Interestingly, BKV showed a high level of LTAg transcript but no expression of the LTAg 
product. The likely explanation for this observation is that there is a high proportion of BKV 
truncated TAg made. Because the position of the forward and reverse primers are upstream of the 
truncated TAg introns, any truncated TAg transcript made would be indistinguishable from large 
T antigen transcript, as visualized on an electrophoresis gel. 
This study found that the amino terminal truncation mutant of the LTAg is necessary and 
sufficient for the upregulation of the interferon response, but the carboxy terminal mutant is 
neither.  The data from Figure 8 shows the ISGs upregulated to the level of the full length T 
antigen.  However the data in Figure 9 reveal that the C257 mutant is unable to induce the 
induction of ISGs.  Together, these data suggest that the activity in the amino terminus of the large 
T antigen is responsible for the induction of the interferon response.   
The binding of pRb family members may be necessary for upregulation of the interferon 
response by T antigen.  Because the activity of T antigen necessary for upregulation of the 
interferon response can be narrowed to within the first 136 amino acids, the elimination of 
activities within the  truncation mutant sequence should abrogate the ability to induce the 
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interferon response.  The data from Figure 19 shows with the loss of pRB binding there is also a 
failure to upregulate STAT1/2 levels.   
Elimination of the small T antigen does not prevent the upregulation of the interferon 
response.  At least two of the three pools expressing polyomavirus LTAg cDNA (or 3/3 for JCV) 
examined were still able to upregulate the interferon response.  Although the structures of SV40 
small T relative to JCV and BKV small T are very different, loss of these proteins did not prevent 
the MEF pools to still upregulate the response in either case.  One interesting question that remains 
is if the small T antigen expressed alone can upregulate the interferon response.  
The expression of STAT1 transcription factor is critical to the upregulation of the interferon 
response and the establishment of the antiviral state.  As shown previously (Horvath 1996), 
STAT1 is necessary for the generation of an antiviral state.  In agreement with those previous 
observations, this study shows that the T antigen induction of the antiviral state depends on STAT1 
transcription factor (Figure 17).  This data also suggests the possibility that T antigen is acting 
upstream of the STAT1 transcription factor. 
Many questions still remain about the mechanism behind the induction of the antiviral 
state.   Because the phenotype seems to be activated with at least the expression amino terminus 
truncation mutant, the activity of T antigen necessary should be limited to this region.  The known 
activity of the region involves the binding of the J domain to the cellular Hsc70 protein to incite 
release of the cellular E2F transcription factors bound to the viral LXCXE motif.  The evidence 
provided in Figure 19 indicates that pRB binding may be necessary for at least the upregulation 
of STAT1/2 total protein levels.  This evidence requires further substantiation to conclude on the 
apparent inability of pRB binding mutants to upregulate the interferon response.  Interestingly, 
examination of clones with cellular E2F knockouts expressing the genomic early region of SV40 
 50 
or SV40 N136, failed to upregulate total STAT1 (data not shown).  Although additional replicates 
have yet to be tested, or have ISG transcripts been examined, this evidence may be indicating that 
somehow the cellular E2Fs, after they are released from pRBs by T antigen, play a role in 
upregulating the interferon response.    
Alternative mechanisms for the upregulated interferon response phenotype are also 
possible.  A recent study by (Ferrero 2014) elucidated the mechanism behind a similar phenotype 
in human BJ-hTERT cells.  They found that the large T antigen mediated DNA damage response 
activates IRF1 signaling inducing the production of IFNβ and subsequent transcription of ISGs 
(Ferrero 2014).  However, because the previous study by Rathi et al. in 2010 indicated that MEFs 
expressing T antigen did not show interferon signal production it can be concluded that mouse 
cells follow a different pathway for the upregulation of the interferon reponse.  This study 
attempted to identify other candidate interferon signals that maybe responsible for activating the 
interferon response, in addition to confirming the previous result by Rathi and others in 2010.  An 
RT-PCR was performed using primers designated for α and β inteferons as described previously 
(Rathi 2010).  Those experiments failed to show interferon production in any pool tested (data not 
shown).  Alternatively one interferon β signal not tested which does bind to the type one interferon 
receptor, interferon β2 (a.k.a. IL-6), was examined.  That experiment showed a uniform level of 
the factor produced across MEFs and MEFs expressing T antigen.  Thus, it seemed as though there 
was no upregulation of the signal with the expression of T antigen versus wt MEFs (data not 
shown).  However, this does not rule out the possibility that IL-6 transcripts are expressed at a 
higher level in T antigen expressing cells.  Another recent study implicates T antigen as a mediator 
of AKT phosphorylation (Yu 2008).  That study suggested that SV40 large T antigen interacted 
directly with insulin receptor substrate-1 (IRS-1), which binds to PI3K, which phosphorylates 
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AKT.  With the elimination of IRS-1 T antigen mediated activation of AKT was also lost.  Most 
interestingly, they showed that T antigen with a mutation for pRB binding was unable to bind IRS-
1 and activate AKT (Yu 2008).  The study by Yu and others is most provocative in light of the 
results produced from this study.  Further investigation into the possible connection between IRS-
1/ T Antigen binding may prove fruitful for understanding the concurrent upregulation of the 
interferon response. 
T antigen upregulation of the interferon response is not necessary for cellular 
transformation. Polyomavirus T antigen is well known for its studies on cellular transformation 
and tumorigenesis (Damania & Pipas 2009).  It was also hypothesized at the beginning of this 
study that T antigen’s upregulation of the interferon response may be related to the onset of cellular 
transformation.  Thus, because it is well known that LTAg and truncations of LTAg will transform 
primary MEFs in vitro, a preliminary experiment was conducted to determine if T antigen 
expressing MEF pools unable to upegulate ISGs would also fail to transform.  An anchorage 
independence assay of a pool of SVTg early region STAT1(-/-) MEFs were examined alongside 
STAT1(-/-) MEFs alone.  The SVTg early region STAT1(-/-) MEFs were able to clearly transform 
the cells in culture and grow independent of anchorage while the STAT1(-/-) MEFs did not.  Based 
on this evidence it appears that STAT1 and ISG upregulation are not related to T antigens ability 
to transform cells. 
A technical challenge was faced during examination of MEF pools throughout this study.  
The pools are actually a “pooling” (i.e. collection) of surviving colonies following drug selection.  
The colonies grow at different rates and have various morphologies.  During early passages there 
are many different types of colonies exhibiting various characteristics. As passaging proceeds, few 
colonies tend to dominant the pool. Eventually, at approximately passage 10+, a single 
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morphology dominates.  This phenomenon has not seemed to result in a major shift in results when 
sample from early passage pools were compared to later passages, however this has not been 
rigorously examined.   
Future studies surrounding the T antigen upregulation of the interferon response/ antiviral 
state will focus on resolving the complete mechanism behind how T antigen relies on STAT1 to 
upregulate ISG transcription without the aid of interferon production.  With that in mind, the 
examination of IFN receptor knockout MEFs expressing T antigen would confirm an IFN 
independent mechanism.  Additionally, some results have indicated that T antigen can interact 
with the membrane associated janus kinases (JAKs).  JAK1 is a kinase upstream of STAT1 
activation.  It has been shown by immunoprecipitation that T antigen from murine polyoma virus 
can directly bind to JAK and alter its activity (Weihua 1998).  However, one consideration take 
must be taken into account on this line of experiments and understanding the mechanism of 
interferon response upregulation by T antigen is the location of the T antigen protein.  The large T 
antigen from polyomavirus is known to be located within the nucleus (Damania & Pipas 2009).  
During this study, immunofluorescence assays using a T antigen specific monoclonal antibody 
confirmed this result (data not shown).   Thus, it is not unreasonable to hypothesize that T antigen 
is somehow manipulating the STAT1 pathway from within the nucleus, and not the cytoplasm. 
The purpose of this study was to investigate polyomavirus T antigens and the upregulation 
of the cellular interferon response. The strategy utilized was to elucidate on the mechanism of T 
antigen’s upregualtion of the interferon response, and determine possible consequences of the 
effect. This study demonstrates that T antigen from multiple polyomaviruses are capable of 
upregulating the cellular interferon response. Additionally, activity within the amino terminus of 
the large T antigen is necessary and sufficient to activate the interferon response.  Large T antigen 
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is not reliant on the carboxy terminal activity, nor the influence of small T antigen.  However, 
STAT1 was shown to be critical for ISG upregulation.  Together, the activity of T antigen results 
in an antiviral state.    Figure 20 models the possible mechanism and relates back to the results 
discussed.    
 
 
 
 
(1) T antigen may interact with JAK to activate STAT1.  (2) T Antigen may interact with STAT1 dimers 
within the cytoplasm. (3) T antigen interacts upstream of STAT1 dimers within the nucleus. (4) T antigen 
interacts with an unknown factor that mediates STAT1 activation. 
Figure 20: Possible models for T antigen activation of the Antiviral State 
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7.0  PUBLIC HEALTH SIGNIFICANCE 
The research presented here offers an opportunity for the advancement of public health. 
Because the mechanism of how T antigen activates the antiviral response is not completely 
understood, there could perhaps be additional cellular factors are at play unbeknownst to biology, 
e.g., a secreted IFN-like signal.  An IFN-like secreted factor that activates an antiviral response 
may be useful as a therapy in treatment of viral, or even, other diseases. Indeed, IFN treatment is 
already widely used to treat many different diseases (Dubois 1983, Yoshida 1999, Korenman 
1991, Lin 1999). Therefore, further study into this mechanism may continue to contribute to 
greater understanding of virology, but also presents an opportunity for new applications in human 
health. 
The human polyomaviruses BKV and JCV pose a significant public health threat.  Both of 
these viruses are estimated to be prevalent in ~70% of adults, and can incite serious disease in 
immunocompromised patients (Antonsson 2013, Egli 2009).  Specifically, BKV has been shown 
to cause neuropathy in renal transplant patients (Kim 2004); JCV infection can result in the 
incidence of progressive multifocal leukoencephalopathy (Aksamit 1986, Padgett 1982).  In order 
to develop more effective therapies against BKV and JCV these viruses must be further examined 
to elucidate prospective targets for therapy. The work presented here contributes to a greater 
understanding of the activities of these polyomaviruses, and therefore allows new insight into 
possible avenues to inhibit the viruses from causing disease.  Thus, this work contributes to the 
overall advancement of public health. 
 55 
BIBLIOGRAPHY 
Abend, J. R., Joseph, A. E., Das, D., Campbell-Cecen, D. B., & Imperiale, M. J. (2009).  
 A truncated T antigen expressed from an alternatively spliced BK virus early mRNA. 
 Journal of General Virology, 90(5), 1238-1245. 
 
Aksamit, A. J., Sever, J. L., & Major, E. O. (1986). Progressive multifocal leukoencephalopathy: 
JC virus detection by in situ hybridization compared with immunohistochemistry. 
Neurology, 36(4), 499-504 
An, P., Sáenz Robles, M. T., & Pipas, J. M. (2012). Large T antigens of polyomaviruses: amazing 
molecular machines. Annual review of microbiology, 66, 213-236. 
Antonsson, A., Pawlita, M., Feltkamp, M. C., Bouwes Bavinck, J. N., Euvrard, S., Harwood, C. 
A., ... & Waterboer, T. (2013). Longitudinal study of seroprevalence and serostability of 
the human polyomaviruses JCV and BKV in organ transplant recipients. Journal of 
medical virology, 85(2), 327-335. 
Balan, V., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Lambiase, L. R., Wiesner, R. H., ... & 
Subramanian, G. M. (2006). Modulation of interferon-specific gene expression by 
albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. 
Antiviral therapy, 11(7), 901. 
Black, P. H., & Rowe, W. P. (1964). Viral studies of SV40 tumorigenesis in hamsters. Journal of 
the National Cancer Institute, 32(1), 253-265. 
Bollag, B., Prins, C., Snyder, E. L., & Frisque, R. J. (2000). Purified JC virus T and T′ proteins 
differentially interact with the retinoblastoma family of tumor suppressor proteins. 
Virology, 274(1), 165-178. 
Bulut, Y., Ozdemir, E., Ozercan, H. I., Etem, E. O., Aker, F., Toraman, Z. A., ... & Firdolas, F. 
(2013). Potential relationship between BK virus and renal cell carcinoma. Journal of 
medical virology, 85(6), 1085-1089. 
Damania, B & Pipas, JM. (2009). DNA Tumor Viruses. New York: Springer-Verlag. 
DeCaprio, J. A. (2009). How the Rb tumor suppressor structure and function was revealed by the 
study of Adenovirus and SV40. Virology, 384(2), 274-284. 
Dubois, M. F., Vignal, M., Le Cunff, M., & Chany, C. (1983). Interferon inhibits transformation 
of mouse cells by exogenous cellular or viral genes. 
 56 
Eddy, B. E., Borman, G. S., Grubbs, G. E., & Young, R. D. (1962). Identification of the oncogenic 
substance in rhesus monkey kidney cell cultures as simian virus 40. Virology, 17(1), 65-
75. 
Egli, A., Infanti, L., Dumoulin, A., Buser, A., Samaridis, J., Stebler, C., ... & Hirsch, H. H. (2009). 
Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood 
donors. Journal of Infectious Diseases, 199(6), 837-846. 
Fensterl, V., Wetzel, J. L., Ramachandran, S., Ogino, T., Stohlman, S. A., Bergmann, C. C., ... & 
Sen, G. C. (2012). Interferon-induced Ifit2/ISG54 protects mice from lethal VSV 
neuropathogenesis. PLoS pathogens, 8(5), e1002712. 
Forero, A., Giacobbi, N. S., McCormick, K. D., Gjoerup, O. V., Bakkenist, C. J., Pipas, J. M., & 
Sarkar, S. N. (2014). Simian Virus 40 Large T Antigen Induces IFN-Stimulated Genes 
through ATR Kinase. The Journal of Immunology, 192(12), 5933-5942. 
Frisque, R. J. (2001). Structure and function of JC virus T'proteins. Journal of neurovirology, 7(4), 
293-297. 
Girardi, A. J., Sweet, B. H., Slotnick, V. B., & Hilleman, M. R. (1962). Development of tumors in 
hamsters inoculated in the neonatal period with vacuolating virus, SV40. Experimental 
Biology and Medicine, 109(3), 649-660. 
Gjoerup, O., & Chang, Y. (2010). Update on human polyomaviruses and cancer. Advances in 
cancer research, 106, 1-51. 
Hallen, L. C., Burki, Y., Ebeling, M., Broger, C., Siegrist, F., Oroszlan-Szovik, K., ... & Foser, S. 
(2007). Antiproliferative activity of the human IFN-α-inducible protein IFI44. Journal of 
Interferon & Cytokine Research, 27(8), 675-680. 
Horvath, C. M., & Darnell, J. E. (1996). The antiviral state induced by alpha interferon and gamma 
interferon requires transcriptionally active Stat1 protein. Journal of virology, 70(1), 647-
650. 
Ivashkiv, L. B., & Donlin, L. T. (2014). Regulation of type I interferon responses. Nature Reviews 
Immunology, 14(1), 36-49. 
Kawai, T., & Akira, S. (2006). Innate immune recognition of viral infection. Nature immunology, 
7(2), 131-137. 
Kim, H. C., Hwang, E. A., Kang, M. J., Han, S. Y., Park, S. B., & Park, K. K. (2004, September). 
BK virus infection in kidney transplant recipients. In Transplantation proceedings (Vol. 
36, No. 7, pp. 2113-2115). Elsevier. 
Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M., & Hoofnagle, J. H. 
(1991). Long-term remission of chronic hepatitis B after alpha-interferon therapy. Annals 
of internal medicine, 114(8), 629-634. 
 57 
Levine, A. J. (2009). The common mechanisms of transformation by the small DNA tumor viruses: 
The inactivation of tumor suppressor gene products:p53. Virology, 384(2), 285-293. 
Lin, R. J., Yu, H. P., Chang, B. L., Tang, W. C., Liao, C. L., & Lin, Y. L. (2009). Distinct antiviral 
roles for human 2′, 5′-oligoadenylate synthetase family members against dengue virus 
infection. The Journal of Immunology, 183(12), 8035-8043. 
Lin, S. M., Sheen, I., Chien, R. N., Chu, C. M., & Liaw, Y. F. (1999). Long‐term beneficial effect 
of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology, 29(3), 
971-975. 
Markovics, J. A., Carroll, P. A., Robles, M. T. S., Pope, H., Coopersmith, C. M., & Pipas, J. M. 
(2005). Intestinal dysplasia induced by simian virus 40 T antigen is independent of p53. 
Journal of virology, 79(12), 7492-7502. 
McNees, A. L., White, Z. S., Zanwar, P., Vilchez, R. A., & Butel, J. S. (2005). Specific and 
quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR. 
Journal of clinical virology, 34(1), 52-62. 
Moal, V., Textoris, J., Amara, A. B., Mehraj, V., Berland, Y., Colson, P., & Mege, J. L. (2012). 
Chronic hepatitis E virus infection is specifically associated with an interferon-related 
transcriptional program. Journal of Infectious Diseases, jis632. 
Munoz-Marmol, A. M., Mola, G., Fernandez-Vasalo, A., Vela, E., Mate, J. L., & Ariza, A. (2004). 
JC virus early protein detection by immunohistochemistry in progressive multifocal 
leukoencephalopathy: a comparative study with in situ hybridization and polymerase chain 
reaction. Journal of Neuropathology & Experimental Neurology, 63(11), 1124-1130. 
Padgett, B. L., & Walker, D. L. (1982). Virologic and serologic studies of progressive multifocal 
leukoencephalopathy. Progress in clinical and biological research, 105, 107-117. 
Pipas, J. M. (2009). SV40: Cell transformation and tumorigenesis. Virology, 384(2), 294-303. 
Rathi, A. V., Cantalupo, P. G., Sarkar, S. N., & Pipas, J. M. (2010). Induction of interferon-
stimulated genes by Simian virus 40 T antigens. Virology, 406(2), 202-211. 
Sadler, A. J., & Williams, B. R. (2008). Interferon-inducible antiviral effectors. Nature Reviews 
  Immunology, 8(7), 559-568. 
 
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. 
 M. (2011). A diverse range of gene products are effectors of the type I interferon antiviral 
 response. Nature, 472(7344), 481-485. 
 
Shah, K. V. (2007). SV40 and human cancer: a review of recent data. International journal of 
cancer, 120(2), 215-223. 
 58 
Sullivan, C. S., & Pipas, J. M. (2002). T antigens of simian virus 40: molecular chaperones for 
viral replication and tumorigenesis. Microbiology and Molecular Biology Reviews, 66(2), 
179-202. 
Trowbridge, P. W., & Frisque, R. J. (1995). Identification of three new JC virus proteins generated 
by alternative splicing of the early viral mRNA. Journal of neurovirology, 1(2), 195-206. 
Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell, 140(6), 
805-820. 
Verma, S., Ziegler, K., Ananthula, P., Co, J. K., Frisque, R. J., Yanagihara, R., & Nerurkar, V. R. 
(2006). JC virus induces altered patterns of cellular gene expression: interferon-inducible 
genes as major transcriptional targets. Virology, 345(2), 457-467. 
Weihua, X., Ramanujam, S., Lindner, D. J., Kudaravalli, R. D., Freund, R., & Kalvakolanu, D. V. 
(1998). The polyoma virus T antigen interferes with interferon-inducible gene expression. 
Proceedings of the National Academy of Sciences, 95(3), 1085-1090. 
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., ... & Omata, M. (1999). 
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance 
program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Annals of 
internal medicine, 131(3), 174-181. 
Yu, Y., & Alwine, J. C. (2008). Interaction between simian virus 40 large T antigen and insulin 
 receptor substrate 1 is disrupted by the K1 mutation, resulting in the loss of large T 
 antigen-mediated phosphorylation of Akt. Journal of virology, 82(9), 4521-4526. 
 
 59 
